Skip to main content
. 2024 Sep 25;33(173):240045. doi: 10.1183/16000617.0045-2024

FIGURE 2.

FIGURE 2

Access to elexacaftor/tezacaftor/ivacaftor (ETI) in Europe through licensing and reimbursement or through special access programmes. Names of countries are abbreviated according to the International Organization for Standardization.